Assessing health and pharmaceutical systems require background information on the size of the population, its demographics and economics, the pharmaceutical market size and the expenditure on health and pharmaceuticals. These key data are parameters that define the requirements that a system has to meet in terms of population coverage and availability of resources.
The percentage of pharmaceutical expenditure out of total health expenditure provides a useful indication on the relative investment in pharmaceuticals compared to other components. The variation on per capita spending on pharmaceuticals between countries is due to differences in the share of generic medicines, prices and consumption pattern among other factors. Benchmarking pharmaceutical expenditure per capita can help identifying inefficiencies in spending. Very low pharmaceutical expenditure per capita can indicate a gap in pharmaceutical service delivery and result in higher morbidity and mortality.
|C1||Demographics, economics, market and expenditure||PAHO data||Public data|
|C1.1||Population in thousand||113 (2020)1|
|C1.3||GDP/Capita (PPP)||$14,489 USD (2020)2|
|C1.4||GINI index for income distribution (source: World Bank)|
|C1.5||Total pharmaceutical market in USD|
|C1.5.1||Percentage of market share by value produced by domestic manufacturers (%)|
|C1.5.2||Percentage of market share by value of imported pharmaceutical products (%)|
|C1.6||Composition of Total Health Expenditure [Public, Private (Out-of-pocket as share of private)|
|C1.7||Total Expenditure on Pharmaceuticals per Habitant (USD)|
|C1.8||Expenditure on Pharmaceuticals as a percentage (%) of health's total expenditure.|
|C1.9||Total Pharmaceutical Expenditure [Public, Private (Out-of-pocket as share of private)]|
|C1.10||Key legislation-health general (E.g. Health Act/Codex)|
|C1.11||Key legislation-pharmaceuticals and other Health Technologies (E.g. Pharmaceutical/Drug Act/Codex)||Key Pharmaceutical Legislations:
1. Food and Drugs Act
2. Medical Products (Regulations) Act
3. Pharmacy Act (2020)
|S1||Demographics, economics, market and expenditure|
|S1.1||Life-expectancy at birth||75 years (2020)3|
|S1.2||Percentage of Adults Aged over 60 years (65 and older)||8.50% (2020)1|
|S1.3||Percentage of children Aged below 15 years (under 14)|
|S1.4||Percentage population served by the public health system:|
|S1.4.1||% of National public insurance|
|S1.4.2||% of Social-security|
|S1.4.3||% of Private security|
|S1.4.4||Other, please describe|
|S1.5||National health expenditure as a % of GDP:||2.06% (2019)4|
|S1.6||Total Health Expenditure/Capita (USD Year)||The General Government Health Expenditure (GGHE) in 2020 was 74 million East Caribbean dollars (27.40 million US dollars) (2020)5|
- 1: World Bank Data Bank
- 2: World Development Indicators, World Bank. GDP per capita (constant 2017, international $)
- 3: Ministry of Health
- 4: World Health Organization. Global Health Expenditure Database (GHED): total health expenditure. Geneva. http:// apps.who. int/nha/database/Select/Indicators/en
- 5: Ministry of Finance PED and PD. Government Budget.
Human resources are one of the six building blocks of the health system. Pharmacy workforce comprises professionals charged with the final custody of medicines, before they are dispensed to patients, as well as ensuring the proper use and administration of medicines. They also be active in the regulation, manufacturing and procurement of medicines.
Currently, there is no recommendation of the number of pharmacists or pharmacy technicians per capita. However, very low numbers of trained human resources per capita in the pharmaceutical sector can indicate gaps in the delivery capacity of the system.
|C2||Human Resources for health||PAHO data||Public data|
|C2.1||Number of physicians per 1,000 population||0.674 (2016)1|
|C2.2||Number of registered radiologists per 100,000 population|
|C2.3||Number of registered pharmacists per 10,000 population||Grenada has a total of 103 registered pharmacists (2020) of which 99 practicing in country. (2020)|
|S2||Human Resources for health|
|S2.1||Number of registered medical physicists per 100,000 population|
|S2.2||Number of registered radiation oncologists per 100,000 population|
|S2.3||Number of registered radiological technologists per 100,000 population|
|S2.4||Number of registered nurses per 10,000 population||49.8 (nurses and midwives) (2016)1|
|S2.5||Number of registered pharmacy technicians per 10,000 population||There is only 1 listed pharmacist assistant at the general hospital. (2020)|
- 1: Grenada HRH Situational Analysis, 2017
Balancing incentives for innovation and manufacturing medicines with affordability of medicines has been a challenge globally. The flexibilities of the World Trade Organization (WTO)’s Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) allow countries protecting public health, including access to medicines. The existing of provisions for the flexibilities in national legislative framework provide relevant information on the country’s ability to enact public health protection.
|C3||Innovation and Intellectual Property Management||PAHO data||Public data|
|C3.1||Is the country a member of the World Trade Organization?||Yes (2020)1|
|C3.2||With reference to the flexibilities and safeguards (TRIPS) contained in national legislation: are there flexibilities related to the Bolar Extension? Specify||National Legislation has not been modified to implement the Trade-Related aspects of Intellectual Property Rights (TRIPS) Agreement and does not contain TRIPS-specific flexibilities or safeguards (2020)|
|C3.3||Are the legal provisions for data exclusivity for pharmaceutical products? (Data Exclusivity)|
|C3.4||Does some kind of relationship exist between the provision of marketing authorization and patent condition of the product presented? (Patent Linkage)|
|C3.5||Are there legal provisions in order to avoid the extension of a patent? (Evergreening)|
|C3.6||Is there a public record of patents, accessible to the public?|
|S3||Innovation and Intellectual Property Management|
|S3.1||Key legislation-intellectual property and data protection|
|S3.2||Key legislation-innovation for health|
|S3.3||With reference to the flexibilities and safeguards (TRIPS) contained in national legislation: are there flexibilities related to the compulsory licensing provisions that can be applied for reasons of public health?||National Legislation has not been modified to implement the Trade-Related aspects of Intellectual Property Rights (TRIPS) Agreement and does not contain TRIPS-specific flexibilities or safeguards (2020)|
|S3.4||Does national legislation have provisions related with the parallel importation?|
|S3.5||Is it part of the State of any free trade agreement / partnership / customs union of bilateral or multilateral agreement, which has a chapter on intellectual property?|
|S3.6||Are there guidelines or procedures in the country that incorporate the public health perspective in the process of evaluating pharmaceutical patent applications? (for example, guidelines for the evaluation of patent applications, prior consent procedures|
- 1: World Trade Organization. Member information, Grenada and the WTO [Internet]. [cited 2022 Feb 20]. Available from: https://www.wto.org/english/thewto_e/countries_e/grenada_e.htm#:~:text=Grenada%20has%20been%20a%20member,GATT%20since%209%20February%201994
Laws and policies are the basis for good governance in the pharmaceutical sector. A national pharmaceutical policy is the explicit commitment of the government towards different policy objectives related to pharmaceuticals. It provides a guidance for action for all actors involved in the pharmaceutical sector. An implementation plan for the policy defines the responsibilities, measurable goals and timeframes of each actor and those overseeing the implementation. The implementation plan should also include the plan for reporting and independent assessment of the implementation progress.
The use of generic medicines and biosimilars is an important opportunity to increase the efficiency of the pharmaceutical sector spending. Policies to promote the use of generics are a corner stone to guide the government and other institutions to implement generic medicines strategies.
|C4||Pharmaceutical Policy||PAHO data||Public data|
|C4.1||National Medicines and other Health Technologies Policy official document (s) exists. (medicines, blood etc). If yes, please write the year of the most recent document (s).||There is a draft National Medicine Policy: Draft Grenada National Pharmaceutical Policy (2015) (2020)|
|C4.2||Does a national medicines policy implementation plan exist?|
|C4.3||Is access to essential medicines/technologies a part of the fulfillment of the right to health, is it recognized in the constitution or is it part of national legislation? If yes to any of these three please provide details|
|C4.4||Official strategy or policy in place for multisource (generics) medicines|
|S4.1||Is the pharmaceutical policy implementation being regularly monitored/assessed?|
|S4.2||National Health Policy (NHP) / Law exists. If yes date|
|S4.3||National Good Governance Policy or transparency framework for governmental institutions and officials exists. If yes, please specify the year.|
|S4.4||Implementation of a functional system of surveillance and control of advertising or inaccurate or unethical information about medicines and other health technologies|
|S4.5||Official strategy or policy for prescription by international common denomination (INN) for medicines|
|S4.6||Official strategy or policy that allows substitution of generics in the public sector|
|S4.7||Official strategy or policy that allows substitution of generics in the private sector|
|S4.8||Market share of multi-source medicines (branded and unbranded generic products) by volume and value in public and private sector|
Access to medicines in one of the intermediate performance goals of a functioning pharmaceutical system. Benchmarking the consumption of medicines across countries with similar epidemiological profiles is useful to indicate possible over- or underutilization of medicines. It is also useful to potentially indicate the increased risk of the development of antimicrobial resistance in the case of antibiotics.
Access to essential medicines should not depend on the financial means of individuals or households and should be guaranteed as a basic right.
|C5||Access of medicines||PAHO data||Public data|
|C5.1||Access to medicines on the National EML is guaranteed without any payment at the point of care, service or dispensing of the medicines.||Some medicines and for certain population groups. The largest program that provides medicines free of charge is the Medication Assistance Programme (MAP) which provides free NCD medicines up to a value of EC $150 monthly to: • People under 16 and over 60-year-old.
• Physically and mentally challenged persons
• Those with an income less than $500 ECD monthly.
• Patient with one of the following conditions: diabetes, hypertension, glaucoma, all cancers, and asthma.
• Other persons referred by the Social Work Department. (2020)
|C5.2||Median availability of tracer essential medicines in the public sector. Provide percentage (%)|
|C5.3||Consumption of tracer medicines by DDD (Daily defined dose per 1,000 inhabitants per day):|
|C5.3.1||Antibiotic (J and J01)|
Regulation is focused on ensuring efficacy, quality and safety of medicines through their life-cycle. Collaboration between countries can increase efficiency and promote human resource capacity building. Countries in the Americas have invested in strengthening regulatory authorities but more work needs to be done.
The Global Benchmarking Tool has been developed to objectively and systematically evaluate regulatory systems across the globe. Indicators in this section are taken from the Global Benchmarking Tool to align with best practice in the field of evaluation of regulatory systems.
|C6||Regulatory Capacity||PAHO data||Public data|
|C6.1||Legislation identifies the institutions involved in regulatory system medicines and other health technologies, their responsibilities, functions, roles and powers. Please, provide the name(s) of the NRA(s)||Institutions involved in reglation are the Ministry of Health, Grenada and The Grenada Pharmacy Council (2020)|
|C6.2||Has the NRA been evaluated by Regional or Global Benchmarking Tool? If yes, has it achieved level 3 of functionality?||No, the country has not been benchmarked or self-assessed against the WHO Global benchmarking tool (2020)|
|C6.3||What category of medicinal products does the NRA regulate? Specify||Medicines, Vaccines, Medical Devices (2020)|
|C6.3.1||Pharmaceuticals of chemical synthesis|
|C6.3.4||Biologicals (e.g. vaccines)|
|C6.4||What functions does the NRA perform?|
|C6.4.1||Registration and Marketing Authorization||The country does not have a marketing authorization process in place nor uses subregional efficiencies such as the Caribbean Regulatory System (2020)|
|C6.4.2||Licensing of premises||Licensing of importers, wholesalers and distributors through the Grenada Pharmaceutical Facility Certification Program is done by the Ministry of Health. (2020)|
|C6.4.3||Market Surveillance and Control||Legal provisions establish a pharmaceutical surveillance that includes the sampling and analysis of samples of medical products (Article 18, Part III, of the Law of Medical Products (Regulations). Since 2018, the country participates in the CARPHA Post Market Surveillance Program through the OECS-PPS. (2020)|
|C6.4.4||Vigilance||There are no legal provisions, regulations, or guidelines to define regulatory framework of vigilance. (2020)|
|C6.4.5||Clinical Trials Oversight|
|C6.4.6||Regulatory Inspection||Inspection requirements are the same for public and private facilities; however, inspections are only a prerequisite for the licensing of private facilities. Inspections are carried out on private wholesalers, retail distributors, public and private pharmacies and stores, and dispensing points. In 2020 a total of 63 inspections took place, 77% in private facilities and the rest in public dispensaries. (2020)|
|C6.4.7||Laboratory Testing||The country does not have a national quality control laboratory, but since 2018 it participates in the CARPHA post market surveillance program. (2020)|
|C6.4.8||NRA Vaccine Lot Release|
|C6.5||Number of employees of the National Regulatory Authrity (NRA) with activities at central level|
|C6.6||Number of medicines with current valid registration||None, the country does not have a medicines registry (2020)|
|C6.7||NRA webpage or website|
|S6.1||Number of licensed national pharmaceutical manufactures||0 (2020)1|
|S6.2||Number of import permits of medicines granted in the last year|
|S6.3||Are there legal provisions that categorize according to the risk to medical devices?|
- 1: Ministry of Health
The goal of an efficient procurement is to ensure the acquisition of the adequate quantities of a quality assured medicines at an affordable price. Achieving this goal can improve access to medicines. Country collaborations in different steps in the procurement process can promote efficiency including negotiation, information exchange and bulk procurement.
Distribution systems have the goal to ensure a steady supply of pharmaceuticals and other health goods. Distribution of goods is an additional costs to the end price patients or the system have to pay. Hence, it is important to design systems that protect the goods from damage and losses, delivery the right quantities at the right time at the lowest cost possible. Assessing procurmenet and supply chain performance is needed on an ongoing basis. The indicators in this section are well established and are routinely used to assess global supply chains.
|C7||Procurement and Supply Chain Management||PAHO data||Public data|
|C7.1||Agency/agencies responsible for public procurement for medicines and medical devices. Please specify||The Ministry of Health has a Central Medical Store responsible for procurement of pharmaceutical and general supplies. Nearly all the public pharmaceutical procurement is done through the OECS Pharmaceutical Procurement Services (OECS/PPS). In 2018, a procurement unit was established in the general hospital. This unit is responsible of procuring other medical supplies exclusively for the hospitals. (2020)|
|C7.2||Is there a program, system or area responsible for the Quality Assurance for the public procurement mechanism for medicines?||OECS does have a quality assurance program that considers prequalification of suppliers, post-marketing surveillance of priority medicines tested at CARPHA Medicine Surveillance and Quality department. However, no criteria or mechanisms to demonstrate the quality, safety and efficacy of the product are required. (2020)|
|C7.3||Number of licensed retail pharmacies per 10,000 population (Private sector).||12 licensed retail outlets total (2020)|
|S7||Procurement and Supply Chain Management|
|S7.1||Number of entities legally authorized to import pharmaceutical products.|
|S7.2||Number of distributors or their agents authorized to operate|
|S7.3||Number of wholesalers licensed|
|S7.4||Is there regulation for sale of pharmaceutical products via the Internet that limited to registered and authorized mail-order pharmacies or other authorized entities?|
Services that the provided by pharmacists or trained pharmacy staff include among other tasks dispensing, health promotion, screening for diseases, administrating medicines and ensuring safe storage and quality supply of medicines.
A system that delivers pharmaceutical services requires adequately trained staff as well as the legal framework at establishes standards for the delivery of medicines. For instance, dispensing of medicines can only be done under the supervision of a trained health professional. Retail stores with medicines dispensing units require an onsite pharmacist to be present throughout the hours of its operation.
The number of private and public pharmacies including hospital pharmacies per inhabitants is an indicators to assess the capacity of a system to provide pharmaceutical services. Information of type of services provided by pharmacies indicates the locations where population can access healthcare.
|C8||Pharmaceutical services||PAHO data||Public data|
|C8.1||Are ther legal provisions that require the presence of the pharmacist in all public and private pharmacies/drug stores?|
|C8.1.1||Full time (Pharmacy working hours)|
|S8.1||Number of hospital pharmacies|
|S8.2||Number of private pharmacies|
|S8.3||Are there any follow-up program of NCD for patients at pharmaceutical care/pharmacies for at least two diseases (e.g. HIV, diabetes, hypertension)?|
Conventional diagnostic radiology (basic and specialized), interventional radiology, sonography, radiation therapy, and diagnostic and therapeutic nuclear medicine are currently playing an essential function in clinical health care processes. These services cover a wide range of clinical applications, from the diagnosis and monitoring of very common diseases and situations with a high incidence, such as respiratory diseases, traumas, digestive disorders, control of pregnancy and breast disorders, etc., to more complex diseases such as tumors, AIDS, central nervous
system conditions, or cardiovascular diseases. International standards also require that countries have a national regulatory infrastructure for radiation safety and protection of patients, health workers and the public in general.
|C9||Radiological regulation and Services||PAHO data||Public data|
|C9.1||Do legal provisions exist that establish the functions and responsibilities of the National Regulatory Authority for radiological safety to protect patients, workers, public, and the environment.|
|C9.2||Annual number of radiological explorations per 1,000 population|
|S9||Radiological regulation and Services|
|S9.1||Radiological Health technologies per 1 million population (public and private sector)|
|S9.1.2||Telecobalt unit (Cobalt-60)|
Universal access to safe blood for transfusions is based on self-sufficiency in blood and blood products through voluntary unpaid donation of blood, improvements in the quality of donated blood, maximization of adequate use of blood, strengthening of human resources.
In addition to the technical aspects, it is necessary for states to ensure the allocation of resources according to national blood safety objectives and plans, reorganize and integrate blood services networks in accordance with the needs of the national health system. That they develop and manage health surveillance, and promote and manage Hemovigilance and risk management, along the chain of transfusion.
Finally, obtaining relevant information through specific indicators allows strengthening the management of information to visualize and determine if there is a sufficient, timely, accessible and safe blood supply, and how this supply is linked to the country's morbidity and mortality.
|C10||Blood regulation and services||PAHO data||Public data|
|C10.1||Is there a specific law that regulates the promotion of donation, processing, storage, use of blood and health surveillance?|
|C10.2||Are the Hemovigilance (HM) activities legally established (roles and responsibilities) for the HM?|
|C10.3||Total Number of whole blood donations collected during the reporting period (by total blood banks, types of donation and frequency).|
|C10.4||Percentage of donations (whole blood and apheresis) that were screened for TTIs|
|C10.5||Percentage of RBC units separated and discarded from the total whole blood units|
The transplant of organs, tissues and cells has become a worldwide practice that can prolong life and improve its quality. Advances in ablation, preservation, transplant and immunosuppression techniques have improved the effectiveness, cost-effectiveness and cultural acceptability of transplants with the consequent increase in demand for these practices. Today it is possible to perform solid organ transplants such as kidney, liver, heart, lung, pancreas, small intestine and cornea mainly, and also treat other events leukemias, severe burns, traumatic accidents and surgical treatment, with the use of cell and tissue transplantation , these treatments have become an effective therapy that saves lives and improves the quality of life of many people. However, despite the great scientific developments and the advances that can be seen in some countries, the capacities for transplants in the different health systems of the Region of the Americas are heterogeneous.
Therefore, having basic information about these transplant therapies allows us to propose a baseline that allows the monitoring of the strategy and plan of action on donation and equitable access to the transplantation of organs, tissues and cells 2019 - 2030 recently. promoted by PAHO, also to know and follow the behavior of equitable and quality access to transplants of organs, tissues and cells in the countries.
|C11||Transplants||PAHO data||Public data|
|C11.1||Does the country have a national organization of transplants with structure, competencies and financing according to the essential responsibilities of the donation and transplant system|
|C11.2||Does the country have a National single registry for the entire health system (public and private), of waiting patients (waiting list), coordinated by the governing body.|
|C11.3||Does the country have documents that establish technical-scientific criteria for the donation, processing and allocation and distribution of organs, tissues and cells.|
|C11.4||Does the country have mechanisms that guarantee the availability of medicines for donation and transplant programs|
Appropriate use of medicines is necessary to achieve health benefits and protect populations from harm cause by medicines. Additionally, inappropriate use of medicines wastes resources. Inappropriate use of medicines include: overuse (using medicines that are unnecessary), underuse (the absence of medicines when they are effective), the wrong use (medicines are not in line with best clinical evidence or wasting resources).
Management tools to promote appropriate use of medicines are formularies or essential medicines lists, standard treatment guidelines and health technology assessments, among others. The development of these tools needs to follow a defined process that is publically available and that manages conflicts for interest if present.
Advertisement of medicines can provide distorted information about medicines that can result in harmful use of medicines. Surveillance of advertisement by regulatory bodies is relevant to prevent harm.
|C12||Rational Use of Medicines and other Health Technologies||PAHO data||Public data|
|C12.1||Does a National Essential Medicines List (EML) exist? If yes, provide the number of medicines on the EML by active ingredient||Grenada does not have a national essential medicine list. Nonetheless, Grenada purchase most of its pharmaceuticals through the OECS/PPS. The OECS/PPS does have a medicine list that is updated regularly. (2020)|
|C12.2||A national Committee on Selection (free of conflict of interests) and Use of Essential Medicines exists.|
|C12.3||Is there a procedure for the selection of medicines of the EML publically available?|
|C12.4||Was the EML updated in the last 5 years?|
|C12.5||Does a National Essential Priority Medical Devices List exist? If yes, provide the number of medical devices listed|
|C12.6||Existence of a national strategy or plan for the rational use of medicines and other health technologies, with monitoring of results||Grenada dos does not have a national policy for the rational use of medicines and other health technologies (2020)|
|C12.7||Incorporation of medicines and other health technologies of the public sector through an official mechanism that includes the selection according to the criteria of Health Technologies Assessment||There is no evidence that the selection of products purchased outside the OECS/PPS follows any established or verified evidence-based criteria. (2020)|
|C12.8||Is there a functional system of surveillance and control of advertising or inaccurate or unethical information about medicines and other health technologies?||There are legal provisions in the Food and Drug Law of a relevant nature for the control of the promotion, marketing and advertising of medical products (Article 4 of Part I). However, this function is not carried out in practices and no relevant guidelines were found for the control of the promotion, marketing and advertising of medical products. (2020)|
|C12.9||Adoption of guidelines and indicators for, at least, good prescribing practices and good pharmacy practices||The country has not adopted guideline for good prescribing practices based on international good practices. Also, the country does not have published guidelines for good pharmacy practice (2020)|
|S12.1||Existence of a current national and functional program of communication and dissemination of independent information on the rational use of medicines and other health technologies|
|S12.2||Existence of official systems for monitoring the safety of medicines and other health technologies (national functional systems of at least two of the following: pharmacovigilance, technovigilance, haemovigilance)||There are no legal provisions, regulations, or guidelines to define regulatory framework of vigilance. (2020)|
|S12.3||Existence of defined standards and procedures for the development or adaptation of clinical practice guidelines||The country lacks the technical capacity to produce Standard Treatment Guidelines (STG) for common diseases using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) as recommended by WHO. However, the country actively participates in subregional efforts, led by the Caribbean Public Health Agency (CARPHA), for the development of clinical guidelines for diabetes in 2019 and for hypertension in 2021. (2020)|
|S12.4||There are Clinical Guidelines in agreement with EML for most common illnesses||No (2020)|
Many medicines are considered essential goods which means that their prices are less influenced by demand. Measuring medicines prices can be challenging but is important to understand affordability which is a key dimension of access. Governments can influence markets that set prices through control of markups or eliminating tariffs and taxes. Governments are often buyers of large quantities of medicines which means that they can effectively negotiate prices and share information with other national or international buyers to increase their power.
Health technology assessments (HTAs) play an important part in the selection of medicines for reimbursement. An HTA consists of a systematic evaluation of the properties, effects, and/or impacts of medicines, devices and other technologies for health. Many countries in the Americas have developed institutional capacity to carry out HTAs to support the selection of technologies for their health systems. However, much needs to be done to improve quality and efficiencies in technology selection for health systems. Country collaborations in this area are vital to reduce costs of conducting HTA.
Treatment coverage is one of the most relevant outcome measures to assess a functioning pharmaceutical system. It is a core indicator of many vertical disease programs such as HIV and TB. Since non-communicable diseases are the top cause of mortality worldwide assessing treatment coverage for common diseases such as hypertension and diabetes is critical in addition to HIV and TB.
|C13||Pricing, Procurement, Health Technology Assessment (HTA) and coverage||PAHO data||Public data|
|C13.1||Are taxes imposed on pharmaceuticals?|
|C13.2||Importation tax. If yes, what percentage?|
|C13.3||VAT (value-added tax) If yes, what percentage?|
|C13.4||Other. Please, describe|
|C13.5||Is there an institution responsible for HTA?|
|C13.6||Does the country have a legal framework for the use of HTA in decision-making? Specify|
|C13.7||Public procurement of medicines is determined by the products selected according to HTA or other evidence-based criteria|
|C13.8||Agency/agencies that sets medicine prices exists. If yes, name.|
|C13.9||Does pricing regulation in the public sector exist?|
|C13.10||Does pricing regulation in the private sector exist?|
|C13.11||Name of the body responsible for selection of products for coverage|
|C13.13||Percentage individuals with raised blood pressure (SBP>= 140 and/or DBP >= 90 mmHG) currently taking medicines for hypertension|
|C13.14||Percentage individuals with raised fasting blood glucose (plasma venous value ≥126 mg/dl) currently on medication for raised blood glucose)|
|C13.15||Opioid consumption in morphine milligrams (mg) per capita/year|
|S13.1||Percentage patients diagnosed with HIV on treatment|
|S13.2||Percentage patients diagnosed with TB concluding treatment course|